Diagnostic value of cfDNA  and long fragment DNA in patients with breast cancer

Haiyan Xu; Guirong Liu

doi:10.14715/cmb/2020.66.7.28

Issue

Vol. 66 No. 7: Issue 7

Issue Published : November 9, 2020

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Diagnostic value of cfDNA and long fragment DNA in patients with breast cancer

https://doi.org/10.14715/cmb/2020.66.7.28

Haiyan Xu

Department of Medical Oncology, The Second People's Hospital of Lianyungang,41 Hailian Road, Lianyungang222000, Jiangsu, China

Guirong Liu

Department of Radiotherapy,The Second People's Hospital of Lianyungang,41 Hailian Road,Lianyungang222000, Jiangsu, China

Corresponding Author(s) : Guirong Liu

wkajt8@163.com

Cellular and Molecular Biology, Vol. 66 No. 7: Issue 7
Article Published : October 31, 2020

Abstract

To investigate the diagnostic value of cell-free DNA (cfDNA) and long fragment DNA in breast cancer patients.Female patients with breast cancer (n = 80) were recruited over one year for this study, and served as an observation group. The control group consisted of 50 normal, healthy females. Plasma levels of cfDNA and long fragment DNA were determined a day before treatment, 7 days after treatment, and on the 20th day of treatment. The levels of cfDNA and long fragment DNA in breast cancer patients before treatment were significantly higher than those of the control group (p<0.05). Patients cfDNA and long fragment DNA levels 7 days after treatment were not significantly different from the corresponding values at 1 day before treatment (p>0.05), but they decreased significantly on the 20th day of treatment, when compared with levels before treatment (p<0.05). Before treatment, the optimal cut-off point for cfDNA in patients' peripheral blood, sensitivity, specificity and accuracy were 12.25ng/mL, 79.12%, 86.15%, and 73.32%, respectively. The area under the ROC curve (AUC) was 0.865 (95% CI = 0.754-0.903). Close monitoring of cfDNA levels in peripheral blood of breast cancer patients in real-time can be used for early diagnosis of the disease.

Keywords

Breast cancer Cell-free DNA Diagnosis Long fragment DNA Plasma.

Xu, H., & Liu, G. (2020). Diagnostic value of cfDNA and long fragment DNA in patients with breast cancer. Cellular and Molecular Biology, 66(7), 186–189. https://doi.org/10.14715/cmb/2020.66.7.28

Download Citation

References

Bin Z, Ling X, Ling X, Liu YH, Zhang MM, Jing RL, et al. Exploratory study of 75 cases of early breast cancer circulating tumor DNA detection using second-generation sequencing technology. Chin J Surg 2017; 55: 847-852.
Mann RM, Kuhl CK, Moy L. Contrast-enhanced MRI for breast cancer screening: Breast MRI for Screening. J Magn Reson Imaging 2019; 22: 126-133.
Brown T, Dyck I, Greenhough B, Raven-Ellison M, Ornstein M, Duffy SW. "They say it's more aggressive in black women”: Biosociality, breast cancer, and becoming a population "at risk”. Trans Inst Br Geogr 2019; 44: 46-51.
Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer: Racial Disparity in Breast Cancer. Cancer 2019; 125: 115-132.
Xiao L, Meng G, Wenzhe S, Li Y, Zhu ZQ. Methylation status of cfDNA ErbB-2 promoter region in peripheral blood of breast cancer and its relationship with tumor Her-2 expression. Chin J Oncol 2015; 7: 14-18.
Chuansheng Y, Zhan H, Zhihui L, Lei RW, Chen ZR, Wu JH, et al. Clinical significance of changes in STC-1 levels in peripheral blood of breast cancer patients. Chin J Oncol 2015; 7: 11-14.
Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysism. Lung Cancer 2016; 2: 24-26.
Pang D, Xia BS, Zhang XY. Clinical application of cell free DNA in breast cancer. Chin J Oncol 2015; 42: 261-264.
Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World J Clin Oncol 2018; 9: 26-32.
Li YL, He JX, Ceng XL, Yuan H. Research progress of clinical significance of plasma free DNA detection. Chin J Lab Med 2019; 42: 318-322.
Shen W, Zhao GQ, Liang ZL, Yellapantula V, Sun S, Tang LFP, et al. Analysis of circulating tumor DNA of archived plasma sarnples. J Clin Oncol 2016; 34: 112-123.
Li P. Study on the Value of Serum cf-DNA in the Early Diagnosis of Cervical Cancer. Med Recapitulate 2016; 22: 1990-1992.
Cuckle H, Benn P, Pergament E. Cell-free DNA screening for fetal aneuploidy as a clinical service. Clin Biochem 2015; 48: 932-941.
Ding CM, Yang ZQ, Luan J, Jin SN. Progress of cell free DNA detection and its clinical application. J Clin Lab Med 2017; 35: 564-569.
Boysen AK, Wettergren Y, Sorensen BS, Taflin H, Gustavson B, Spindler KG. Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumor Biol 2017; 39: 3-4.
Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015; 372: 1589-1597.
Jiang X, Zhao C, Fan X, Xu W, Zhang R, Xu HB, et al. A DNA-modified hydrogel for simultaneous purification, concentration and detection of targeted cfDNA in human serum. RSC Adv 2019; 9: 428-432.
Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo SS, et al. Circulating cell- free DNA and its integrity as a prognostic marker for breast cancer. Springerplus 2015; 4: 265ï¼Ž
Mirtavoos-Mahyari H, Ghafouri-Fard S, Khosravi A, Motevaseli E, Esfahani-Monfared Z, Seifi S, et al. Cell free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer. Clin Transl Med 2019; 8: 81-87.
Ding L, Zhao C, An J, Wang YH, Han H. New progress of plasma free DNA in clinical application. Adv Mod Biomed 2016; 22: 3593-3596.
Macagno N, Fina F, Penel N, Bouvier C, Nanni I, Duffaud F, et al. Proof of concept: Prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR. Oncotarget 2018; 9: 88-96.
Gu YF, Zhu ZL, Zhang JY, Zhang M, Zhang XX, Zhu JW. Clinical application of plasma free DNA content and integrity in breast cancer. Lab Med 2017; 32: 671-676.
Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, et al. Cell- free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 2016; 155: 139-149.
Ye K, Zhang LS, Liu C. Clinical significance of plasma free DNA content in the diagnosis of breast cancer. Health Today 2015; 14: 433.
Jia DJ, Wang LJ, Chen XF, Liu Y, Dai JL, Song J. Clinical value of total cfDNA concentration and long fragment DNA concentration in peripheral venous blood of operable non-small cell lung cancer patients. Med Inf 2019; 32: 99-101.
Yang X, Zhang K, Zhang C, Peng R, Sun C. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. BMC Cancer 2019; 19: 465.
Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, et al. Cell free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Breast Cancer Res Treat 2018; 169: 1-14.
Tan G, Chu C, Gui X, Li J, Chen Q. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis. Medicine 2018; 97: 197.
Huang YF, Chen YJ, Fan TC, Chang NC, Chen YJ, Midha MK, et al. Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females. BMC Med Genomics 2018; 11: 16.

References

Bin Z, Ling X, Ling X, Liu YH, Zhang MM, Jing RL, et al. Exploratory study of 75 cases of early breast cancer circulating tumor DNA detection using second-generation sequencing technology. Chin J Surg 2017; 55: 847-852.

Mann RM, Kuhl CK, Moy L. Contrast-enhanced MRI for breast cancer screening: Breast MRI for Screening. J Magn Reson Imaging 2019; 22: 126-133.

Brown T, Dyck I, Greenhough B, Raven-Ellison M, Ornstein M, Duffy SW. "They say it's more aggressive in black women”: Biosociality, breast cancer, and becoming a population "at risk”. Trans Inst Br Geogr 2019; 44: 46-51.

Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer: Racial Disparity in Breast Cancer. Cancer 2019; 125: 115-132.

Xiao L, Meng G, Wenzhe S, Li Y, Zhu ZQ. Methylation status of cfDNA ErbB-2 promoter region in peripheral blood of breast cancer and its relationship with tumor Her-2 expression. Chin J Oncol 2015; 7: 14-18.

Chuansheng Y, Zhan H, Zhihui L, Lei RW, Chen ZR, Wu JH, et al. Clinical significance of changes in STC-1 levels in peripheral blood of breast cancer patients. Chin J Oncol 2015; 7: 11-14.

Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysism. Lung Cancer 2016; 2: 24-26.

Pang D, Xia BS, Zhang XY. Clinical application of cell free DNA in breast cancer. Chin J Oncol 2015; 42: 261-264.

Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World J Clin Oncol 2018; 9: 26-32.

Li YL, He JX, Ceng XL, Yuan H. Research progress of clinical significance of plasma free DNA detection. Chin J Lab Med 2019; 42: 318-322.

Shen W, Zhao GQ, Liang ZL, Yellapantula V, Sun S, Tang LFP, et al. Analysis of circulating tumor DNA of archived plasma sarnples. J Clin Oncol 2016; 34: 112-123.

Li P. Study on the Value of Serum cf-DNA in the Early Diagnosis of Cervical Cancer. Med Recapitulate 2016; 22: 1990-1992.

Cuckle H, Benn P, Pergament E. Cell-free DNA screening for fetal aneuploidy as a clinical service. Clin Biochem 2015; 48: 932-941.

Ding CM, Yang ZQ, Luan J, Jin SN. Progress of cell free DNA detection and its clinical application. J Clin Lab Med 2017; 35: 564-569.

Boysen AK, Wettergren Y, Sorensen BS, Taflin H, Gustavson B, Spindler KG. Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumor Biol 2017; 39: 3-4.

Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015; 372: 1589-1597.

Jiang X, Zhao C, Fan X, Xu W, Zhang R, Xu HB, et al. A DNA-modified hydrogel for simultaneous purification, concentration and detection of targeted cfDNA in human serum. RSC Adv 2019; 9: 428-432.

Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo SS, et al. Circulating cell- free DNA and its integrity as a prognostic marker for breast cancer. Springerplus 2015; 4: 265ï¼Ž

Mirtavoos-Mahyari H, Ghafouri-Fard S, Khosravi A, Motevaseli E, Esfahani-Monfared Z, Seifi S, et al. Cell free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer. Clin Transl Med 2019; 8: 81-87.

Ding L, Zhao C, An J, Wang YH, Han H. New progress of plasma free DNA in clinical application. Adv Mod Biomed 2016; 22: 3593-3596.

Macagno N, Fina F, Penel N, Bouvier C, Nanni I, Duffaud F, et al. Proof of concept: Prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR. Oncotarget 2018; 9: 88-96.

Gu YF, Zhu ZL, Zhang JY, Zhang M, Zhang XX, Zhu JW. Clinical application of plasma free DNA content and integrity in breast cancer. Lab Med 2017; 32: 671-676.

Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, et al. Cell- free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 2016; 155: 139-149.

Ye K, Zhang LS, Liu C. Clinical significance of plasma free DNA content in the diagnosis of breast cancer. Health Today 2015; 14: 433.

Jia DJ, Wang LJ, Chen XF, Liu Y, Dai JL, Song J. Clinical value of total cfDNA concentration and long fragment DNA concentration in peripheral venous blood of operable non-small cell lung cancer patients. Med Inf 2019; 32: 99-101.

Yang X, Zhang K, Zhang C, Peng R, Sun C. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. BMC Cancer 2019; 19: 465.

Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, et al. Cell free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Breast Cancer Res Treat 2018; 169: 1-14.

Tan G, Chu C, Gui X, Li J, Chen Q. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis. Medicine 2018; 97: 197.

Huang YF, Chen YJ, Fan TC, Chang NC, Chen YJ, Midha MK, et al. Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females. BMC Med Genomics 2018; 11: 16.

Author biographies is not available.